All articles tagged with #amyloid b
Blocking the protein PTP1B improved learning and memory in a mouse model of Alzheimer's by boosting microglial clearance of amyloid-β plaques through enhanced SYK signaling; because PTP1B is also tied to obesity and diabetes, this approach could address multiple disease pathways and be combined with existing Alzheimer's treatments, with DepYmed, Inc. collaborating to develop the inhibitors.
The piece chronicles how the once-dominant amyloid-β hypothesis has been undermined by multiple retractions and high-profile drug failures, fueling debate over data integrity and regulatory controversy. While FDA-approved antibodies targeting amyloid-β have had limited or questionable benefits and come with serious risks, researchers are increasingly exploring alternatives—such as neuroinflammation, infections, the gut microbiome, and APOE4-related pathways—suggesting Alzheimer's may result from multiple interacting factors rather than a single cause. The article highlights the persistence of amyloid research despite misconduct findings and casts doubt on a simple cure tied to amyloid-β clearance.
Researchers at Cold Spring Harbor Laboratory found that inhibiting the enzyme PTP1B improves brain microglial function and helps clear amyloid-β plaques in mice, potentially slowing memory decline in Alzheimer's disease. The study suggests PTP1B inhibitors could be paired with existing therapies, with ongoing work to develop such inhibitors for clinical use.
A study has found that the APOEε4 gene variant, a major risk factor for Alzheimer's disease, enhances the effects of amyloid-β on the progression of tau pathology in the brain. The research, conducted on a large cohort of individuals, suggests that APOEε4 may contribute to the development and severity of Alzheimer's disease by exacerbating the accumulation of tau tangles, a hallmark of the disease. These findings highlight the importance of understanding the interaction between amyloid-β and tau in Alzheimer's pathology and may aid in the development of targeted therapies and improved biomarkers for the disease.